NCT00244504

Moxonidine in Patients Undergoing Vascular Surgery

The Effects of Small Doses of Moxonidine in Patients Undergoing Vascular Surgery

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 141 (actual)
• Sponsor: University Hospital, Basel, Switzerland · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Investigating the perioperative effect of moxonidine. In a randomized double-blind fashion, patients undergoing vascular surgery will receive moxonidine 0.2 mg or placebo from the day before surgery until day 4 after surgery. Holter-EKG for 48 h, starting just before surgery. Repeated 12-lead EKG, measurements of Troponin I and BNP, clinical visitations, follow-up interviews at 6 and 12 months

Conditions

• Cardiac Disease
• Vascular Surgery

Interventions

Type	Name	Description
DRUG	moxonidine	moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery

Timeline

• Start date: 2002-11-01
• Primary completion: 2006-03-01
• Completion: 2006-03-01
• First posted: 2005-10-26
• Last updated: 2009-11-10

Locations

1 site across 1 country: Switzerland